Journal article
Use of a Mobile Health (mHealth) Platform for Remote Assessment of Suicidal Ideation, Depression, and Anxiety: A Longitudinal Retrospective Study
Innovations in digital health, diagnostics, and biomarkers, v 2(2022), pp 8-15
01 Jan 2022
Abstract
ABSTRACT
Introduction
There is growing support for the use of integrated measurement-based care to capture symptom data in real time so treatment providers can make informed decisions about intervention strategies for mental health problems, such as depression and anxiety, both of which are known to increase suicide. We examined the potential scalability and effectiveness of a mobile health (mHealth) application with integrated behavioral health functions to capture remote patient-reported measurement of suicidal ideation and overall symptoms of depression and anxiety.
Methods
This study was an observational retrospective review of deidentified patient data, including symptoms of suicidal ideation, depression, and anxiety as measured by the Patient Health Questionnaire-9 (PHQ-9) or Generalized Anxiety Disorder 7 (GAD-7) scale, which were administered to and completed by patients on a smartphone or desktop application. After controlling for age, sex, and the presence of moderate versus severe symptoms at baseline, mean scores were analyzed with the Student's t-test.
Results
Of patients who took the PHQ-9 assessment at baseline and 8 weeks later (n = 764), the proportion who endorsed suicidal thinking decreased from 25% to 14.66% (p < 0.001) over 8 weeks. The mean PHQ-9 score was reduced from 14.69 (standard error [SE], 4.09) to 10.50 (SE, 5.94; p < 0.001), and a subset of individuals who continued use and took the PHQ-9 again at 24 weeks (n = 185) had a further decrease to 9.03 (SE, 7.09, p < 0.01). Although 21.62% of this subset still had suicidal thinking, the frequency of suicidal thoughts decreased. Of patients who took the GAD-7 at baseline and 8 weeks (n = 797) the mean score decreased from 14.20 (SE, 3.31) to 10.08 (SE, 5.55; p < 0.001) at 8 weeks and to 7.48 (SE, 6.54; p < 0.001) for a subset (n = 278) who continued use and took a GAD-7 at 24 weeks (n = 278). The sum of subgroup samples is larger than the whole because of instances of comorbid depression and anxiety.
Conclusion
Remote assessments within technology-supported integrated behavioral health care were feasible at scale. Change in symptoms could be observed at the individual and group level in real time, which may allow clinical teams to adjust treatments and improve outcomes. Prospective controlled studies are needed to determine what factors contribute to reductions in symptom severity.
Metrics
6 Record Views
Details
- Title
- Use of a Mobile Health (mHealth) Platform for Remote Assessment of Suicidal Ideation, Depression, and Anxiety: A Longitudinal Retrospective Study
- Creators
- Adam Pardes - NeuroFlow, Inc, Philadelphia, PA, USAWilliam Lynch - NeuroFlow, Inc, Philadelphia, PA, USAMatthew Miclette - NeuroFlow, Inc, Philadelphia, PA, USAEllen McGeoch - NeuroFlow, Inc, Philadelphia, PA, USABrian P Daly - NeuroFlow, Inc, Philadelphia, PA, USA
- Publication Details
- Innovations in digital health, diagnostics, and biomarkers, v 2(2022), pp 8-15
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Psychological and Brain Sciences (Psychology); School of Education
- Other Identifier
- 991021893683004721